Suppr超能文献

与潜伏性结核相关的葡萄膜炎:抗结核治疗联合或不联合全身糖皮质激素的疗效比较研究

Uveitis associated with latent tuberculosis: A comparative study of the impact of antitubercular therapy combined or not with systemic corticosteroids.

作者信息

Nahon-Esteve Sacha, Martel Arnaud, Maschi Celia, Alketbi Mohamed, Baillif Stephanie, Tieulie Nathalie

机构信息

Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Department of Ophthalmology, Nice, France.

出版信息

Eur J Ophthalmol. 2021 Sep;31(5):2457-2466. doi: 10.1177/1120672120962066. Epub 2020 Oct 2.

Abstract

PURPOSE

To study the outcome of latent tubercular uveitis (LTBU) treated with antitubercular therapy (ATT) combined or not with adjuvant systemic corticosteroids.

METHODS

Twenty patients (27 eyes) with LTBU were included in a monocentric retrospective study and evaluated for the absence of active disease after treatment. Data on the clinical outcomes (active inflammation), vision (best-corrected visual acuity, BCVA) and treatment were collected retrospectively.

RESULTS

Fourteen patients received ATT alone and six patients received ATT combined with systemic corticosteroids. The two groups were not comparable in terms of proportion of tubercular panuveitis cases and initial BCVA (59.3 ± 8.2 letters vs 44.2 ± 15.2 letters). There was no significant difference in remission rate and in BCVA between both groups 3 months after ATT discontinuation.

CONCLUSION

Patients with LTBU treated with ATT alone had visual and inflammatory outcomes at least comparable to those of patients treated with ATT combined with systemic corticosteroids.

摘要

目的

研究抗结核治疗(ATT)联合或不联合辅助全身用糖皮质激素治疗潜伏性结核性葡萄膜炎(LTBU)的疗效。

方法

20例(27只眼)LTBU患者纳入一项单中心回顾性研究,并评估治疗后无活动性疾病的情况。回顾性收集临床结局(活动性炎症)、视力(最佳矫正视力,BCVA)和治疗的数据。

结果

14例患者仅接受ATT治疗,6例患者接受ATT联合全身用糖皮质激素治疗。两组在结核性全葡萄膜炎病例比例和初始BCVA方面不具有可比性(59.3±8.2字母对44.2±15.2字母)。停用ATT 3个月后,两组的缓解率和BCVA均无显著差异。

结论

仅接受ATT治疗的LTBU患者的视力和炎症结局至少与接受ATT联合全身用糖皮质激素治疗的患者相当。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验